The nation of Zimbabwe has rejected a major US health deal worth $367m (272 million pounds) spanning five years because of Washington's request for sensitive biological samples.
This rejection came to light following a official document from December was disclosed, indicating that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official spokesperson has since stated that the US was requesting biological samples for research and profit but was not willing to share the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for more negotiations to find a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
This rejection comes after a comparable situation in Kenya, where a high court halted a related deal with the US following concerns were filed about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 nations in Africa have so far agreed to similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, without any equivalent guarantee of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would provide the basic resources for medical research with no certainty that the final treatments would be accessible to our population should a future health crisis arise."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures previously set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is designed to guarantee that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that talks need to persist since a large portion of the country's Aids initiatives were funded by international support.
"If specific concerns exist, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it added.
The halted deal highlights the complex tensions between receiving much-needed international aid and safeguarding a country's data in an ever more interconnected world.